Pyxis Oncology, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
PYXS Nasdaq 2836 www.pyxisoncology.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Pyxis Oncology, Inc.

Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering - Oct 2nd, 2026 5:00 am
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering - Sep 29th, 2026 11:11 pm
Pyxis Oncology stock falls on public offering announcement - Sep 29th, 2026 3:19 pm
Pyxis Oncology Announces Proposed Public Offering - Sep 29th, 2026 2:24 pm
Pyxis Oncology shares fall 7% despite updated MICVO trial results - Sep 9th, 2026 8:08 am
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) - Sep 9th, 2026 5:00 am
Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) - Sep 8th, 2026 2:01 pm
Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board - Sep 8th, 2026 5:30 am
Pyxis Oncology to Participate in Upcoming Investor Conferences - Sep 1st, 2026 5:30 am
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones - Aug 13th, 2026 5:00 am
Pyxis Oncology Secures Up to $114 Million Private Placement - Jun 30th, 2026 8:30 am
Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones - Jun 30th, 2026 5:30 am
Analysts See Nearly 3X Upside in Pyxis Oncology (PYXS) - Jun 10th, 2026 12:22 pm
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones - May 14th, 2026 5:00 am
Creative Global Technology Holdings And 2 Other Promising Penny Stocks - May 12th, 2026 6:04 am
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer - May 7th, 2026 2:05 pm
NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA - May 6th, 2026 6:35 am
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026 - Apr 17th, 2026 2:05 pm
3 Penny Stocks With Market Caps Under $400M To Consider - Apr 13th, 2026 12:05 pm